Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ gives an overview of his talk on the management and treatment of high-risk multiple myeloma (MM) patients. According to Prof Stewart, high-risk features can be found in approximately 15-25% of patients and include the 17p deletion, serum translocations, and the alleviation of LDH in the peripheral blood. Prof Stewart further discusses how to treat high-risk patients and this includes triplet therapy, the importance of achieving a molecular complete remission (CR), the role of a second transplant and the promise of immunotherapy.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.